AHERF EV Biofoundry — Diagnostics to CommercializationEV BiofoundryCliniConnectServicesStart an Enquiry
CliniConnect Platform

Clinical access, programs and disease consortia

CliniConnect is the clinical support platform of the AHERF EV Biofoundry. It structures clinical questions, evaluates cohort and biospecimen feasibility, and connects clinicians with disease programs, ethics pathways and Biofoundry execution.

Clinical Access

For clinicians, departments and disease groups entering AHERF-CMBRC through CliniConnect and clinical consortiums.

Clinical Access→CliniConnect→Consortiums→Platform linkage
Open Clinical Access

Clinical Programs

For visitors exploring disease-focused translational programs in neurology and brain tumors, oncology, renal disease, reproductive and child health, ophthalmology, endocrinology and precision medicine.

Clinical Programs→7 disease programs→Disease focus areas→Program focus
Open Clinical Programs
Clinical Programs

Disease-focused translational programs for biomarker and precision medicine development

program governance: All CliniConnect-linked clinical programs are housed under CliniConnect. This Research section describes disease-focused scientific programs, while CliniConnect manages clinical entry, cohort linkage, biospecimens, metadata, ethics pathways and program participation.

Clinical Programs describes the disease-area portfolio. These programs connect clinical clinical programs with EV science, biomarker profiling, liquid biopsy, clinical AI and multimodal translational research.

Propose a disease programEnter through CliniConnect
Disease focus areas
Alzheimer’s diseaseDementia spectrum disordersParkinson’s diseaseMultiple sclerosisALS / motor neuron diseaseTraumatic brain injuryBrain ageing and cognitive declineNeuroinflammationGliomaGlioblastomaMeningiomaPediatric brain tumorsCNS metastatic diseaseImaging-linked biomarker models
Program focus: neuronal/CNS-enriched EVs, amyloid biology, tau biology, neurodegeneration markers, synaptic injury, inflammatory signatures, genetics where applicable, CNS tumor-derived EVs, liquid biopsy concepts and longitudinal brain-health or tumor-monitoring models. Solid-tumor focus includes oral, prostate, breast, renal and other cancers; early detection; recurrence and residual-disease monitoring; and therapy-response biomarkers.
Oral cancersProstate cancerBreast cancerRenal cancersOther solid tumorsTherapy-response monitoringRecurrence and residual disease conceptsCompanion diagnostic exploration
Kidney graft rejectionDiabetic nephropathyChronic kidney diseaseRenal inflammationFibrosis markersImmune activationNon-invasive graft surveillance concepts
Program focus: tumor-derived EVs, cfDNA/ctDNA integration, protein and transcript biomarker panels, recurrence monitoring, treatment-response signatures, resistance biology and companion diagnostic pathways. Renal focus includes urinary EVs, blood and urine renal injury biomarkers, immune activation, graft surveillance, fibrosis panels and diabetic kidney disease risk profiling.
Disease focus areas
Gestational diabetesPCOSInfertility and IVF biomarker researchPregnancy-associated metabolic riskPediatric metabolic riskPediatric inflammatory disordersPediatric immune disordersMaternal-child biomarker models
Program focus: maternal and child health biomarkers, EV and liquid biopsy approaches in reproductive biology, metabolic and inflammatory risk markers, early stratification, non-invasive monitoring and clinical-hormonal-molecular integration.
Disease focus areas
PterygiumDiabetic retinopathyRefractive disordersOcular hypertensionCataractGlaucomaOcular surface diseaseRetinal biomarker programsNeuro-ophthalmic biomarker programs
Program focus: tear-derived EVs, ocular surface biomarker profiling, inflammatory and fibrovascular marker panels, non-invasive tear-based sampling workflows, diabetic eye disease risk models and eye-brain / eye-metabolism links.
Disease focus areas
Type 2 diabetesInsulin resistanceMetabolic syndromeObesity-linked metabolic riskFatty liver / MASLD riskDyslipidemiaThyroid-related metabolic riskCardiometabolic risk models
Program focus: early metabolic-risk biomarkers, inflammatory and endocrine signatures, EV and liquid biopsy approaches, longitudinal glucose-metabolic monitoring concepts, and multimodal cardiometabolic risk models.
Disease focus areas
Cross-disease biomarker integrationLiquid biopsy beyond oncologyEV + cfDNA + protein + transcript panelsClinical metadata integrationImaging integration where applicableAI-enabled risk scoresLongitudinal monitoring modelsMultimodal integrated risk models
Program focus: integrated disease-risk models, composite biomarker scores, predictive and prognostic models, treatment-response prediction, longitudinal tracking and clinician-readable decision-support outputs.
Connected ecosystem: Disease-area programs are supported by clinical access, science platforms, EV workflows, biomarker development and clinical AI.

Propose or expand a disease program

Use Clinical Programs when the goal is to build or expand a disease-area translational program.

Propose a programEnter through CliniConnect
Infectious Disease & Immunology

Host-response biomarkers, immune monitoring, infection-associated inflammation and translational assay development.

Host-response biomarkersImmune monitoringInflammatory signaturesVaccine-response biomarkersImmunomodulation
Program focus: Infection-associated immune and inflammatory signatures, EV-linked immunology, vaccine-response assessment and translational assay concepts.
Capability

Science & Platforms

Choose a science domain or execution stack, then open the detailed capability layer only when you need the methods, sub-capabilities and outputs.

Science

What AHERF-CMBRC works on scientifically.

Science8 domains
Open Science

Platforms

How AHERF-CMBRC executes the science.

Platforms4 platform areasEV-Works depthoutputs
Open Platforms

Science Domains

Science explains the scientific domains: EV biology, biomarkers, diagnostics, liquid biopsy, cell-free therapeutics, vaccines, drug delivery, multi-omics and clinical AI.

8 scientific domains
Extracellular vesicle and liquid biopsy research visual with a blood sample and molecular diagnostic motifs
capabilities
EV biologyExosome-enriched systemsEV cargo biologyDisease-associated EV signaturesEVs in diagnosticsEVs in therapeuticsEVs in immune modulationEV standardization science
Extracellular vesicles are positioned as a central biological system for understanding disease communication, biomarker release, immune signalling, therapeutic delivery and precision diagnostics. This pillar anchors AHERF-CMBRC’s work in EV biology, exosome-enriched workflows and EV applications across diagnostics, therapeutics and translational medicine.
capabilities
EV cargo biomarkersProtein biomarkersTranscript biomarkerscfDNA / ctDNA-linked markersInflammatory signaturesImmune signaturesMulti-marker panelsEarly detection biomarkersPrognostic biomarkersMonitoring biomarkers
This pillar focuses on identifying and developing disease-linked molecular signatures for early detection, risk stratification, prognosis, treatment response and longitudinal monitoring. Biomarker discovery may include EV cargo, proteins, transcripts, nucleic acids, immune signatures and multi-marker panels.
capabilities
EV-based diagnosticsBlood-based liquid biopsyUrine-based liquid biopsySaliva-based liquid biopsyTear-based liquid biopsycfDNA / ctDNA integrationProtein and transcript panelsMolecular diagnostic panelsRisk-score modelsReportable diagnostic concepts
This pillar covers the scientific foundation for non-invasive and minimally invasive diagnostics across oncology, neurology, renal disease, ophthalmology, reproductive health and precision medicine. It includes EV-based diagnostics, liquid biopsy, molecular panels and reportable diagnostic concepts.
capabilities
EV therapeuticsExosome-based therapeutic conceptsStem-cell-derived EVsImmune-cell-derived EVsRegenerative medicine conceptsAnti-inflammatory EV effectsTissue repair biologyPotency-linked biological readoutsSafety and comparability concepts
This pillar covers therapeutic approaches where biological activity is mediated through extracellular vesicles, exosomes or other cell-free systems. The focus includes regenerative medicine, anti-inflammatory effects, tissue repair biology, potency-linked assays and translational therapeutic concepts.
capabilities
EV-based vaccine conceptsAntigen-presentation biologyImmune activation signaturesImmune suppression and toleranceCancer vaccine conceptsInfection vaccine conceptsVaccine-response biomarkersImmune monitoring panelsAdjuvant-like EV functions
This pillar covers translational immunology, immune-response profiling, vaccine concepts, cancer immunology, infection-related immune monitoring and EV-mediated immunomodulation. It links immune biology with biomarker development, vaccine-response assessment and therapeutic immune modulation.
capabilities
EV-mediated drug deliveryExosome-loaded therapeuticsRNA / miRNA / siRNA deliveryProtein and peptide deliverySmall-molecule loadingTargeted delivery conceptsBlood–brain barrier delivery conceptsFormulation scienceStability science
This pillar covers EV and cell-free delivery systems for therapeutic transport, payload loading, targeting, formulation and stability. It includes nucleic acid delivery, protein and peptide delivery, small-molecule loading and disease-specific delivery concepts such as blood–brain barrier targeting.
capabilities
GenomicsTranscriptomicsProteomicsEV cargo profilingImmune profilingInflammatory profilingMetabolite / lipid-associated signalsClinical phenotype integrationMulti-marker biological signatures
This pillar supports biomarker, diagnostic and therapeutic programs through molecular profiling. It integrates genomics, transcriptomics, proteomics, EV cargo profiling, immune signatures, inflammatory signals and clinical phenotype data to generate disease-relevant biological signatures.
capabilities
Biomarker modellingComposite risk scoresPredictive modelsPrognostic modelsTreatment-response modellingPatient stratificationClinical decision-support conceptsLongitudinal monitoring modelsMultimodal integrated risk models
This pillar focuses on transforming biomarker, EV, molecular, clinical and imaging-linked data into interpretable risk models, predictive tools, disease-monitoring frameworks and clinician-readable decision-support concepts.